IAP2/BIRC3 Cancer Research Results

IAP2/BIRC3, cIAP2, cellular Inhibitor of Apoptosis Protein 2: Click to Expand ⟱
Source:
Type:
IAP2 (cellular Inhibitor of Apoptosis Protein 2) is a member of the Inhibitor of Apoptosis (IAP) protein family.
• Like its family members, IAP2 functions to regulate cell survival primarily by inhibiting caspases and other components of the apoptotic machinery.
• IAP2 also influences signaling pathways, such as NF-κB, which affects inflammatory responses, cell proliferation, and survival.

• Overexpression or dysregulation of IAP2 has been observed in various malignancies.
– Elevated IAP2 levels can help tumor cells evade apoptosis, promoting tumor growth and survival.
– IAP2, similar to IAP1, may contribute to resistance against chemotherapies and targeted therapies by blocking cell death pathways.

BIRC3 - Baculoviral IAP Repeat Containing 3 / Cellular Inhibitor of Apoptosis Protein 2

Abbreviation: BIRC3, cIAP2

Type: Inhibitor of apoptosis protein / E3 ubiquitin ligase

Function: BIRC3/cIAP2 regulates apoptosis, inflammatory signaling, and cell survival through ubiquitination-dependent control of TNF receptor and NF-κB signaling pathways. It interacts with proteins including TRAF2 and RIPK1 and helps determine whether TNF-family signaling promotes survival, inflammation, or programmed cell death.

Cancer: ↕ Context-dependent. Increased BIRC3 can suppress apoptosis, activate NF-κB survival signaling, and promote resistance to chemotherapy and radiotherapy in several cancers. However, BIRC3 can also function as a tumor suppressor, particularly in some B-cell malignancies, where deletion or inactivating mutation is associated with increased NF-κB signaling, aggressive disease, and treatment resistance.
CLL, Chronic Lymphocytic Leukemia: Click to Expand ⟱
CLL is a type of cancer that affects the lymphoid cells, which are a type of white blood cell. It is characterized by the accumulation of mature, but dysfunctional, lymphocytes in the bone marrow, lymph nodes, and spleen. CLL is typically a slow-growing disease, and many patients may not experience symptoms for years after diagnosis.
Scientific Papers found: Click to Expand⟱
5150- GamB,    Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-κB signaling pathway
- in-vitro, CLL, KBM-5 - in-vitro, Nor, HEK293
Apoptosis↑, ChemoSen↑, IAP1↓, IAP2/BIRC3↓, Bcl-2↓, Bcl-xL↓, TRAF1↓, cycD1/CCND1↓, cMyc↓, COX2↓, MMP9↓, angioG↓, VEGF↓, NF-kB↓, eff↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Core Metabolism/Glycolysis(tgid=4) ⓘ

cMyc↓, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↑, 1,   Bcl-2↓, 1,   Bcl-xL↓, 1,   IAP1↓, 1,   IAP2/BIRC3↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

cycD1/CCND1↓, 1,  

Migration(tgid=13) ⓘ

MMP9↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,   VEGF↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2↓, 1,   NF-kB↓, 1,   TRAF1↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ChemoSen↑, 1,   eff↓, 1,  
Total Targets: 15

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: IAP2/BIRC3, cIAP2, cellular Inhibitor of Apoptosis Protein 2
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:50  Cells:%  prod#:%  Target#:980  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page